(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 33.88% in 21 sessions from €0.12 to €0.08 at 08:12 EST on Wednesday, following the last session’s upward trend. BEL 20 is rising 0.46% to €3,558.79, following the last session’s upward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).
More news about BIOSENIC (BIOS.BR).
